Glenmark’s Remogliflozin Hopes To Shake Up Indian SGLT2i Market

Glenmark’s remogliflozin is priced about 50% lower than the other SGLT2 inhibitors in India and is expected to expand access to the class of drugs significantly. Early physician outlook for the new SGLT2 inhibitor appears encouraging.